Partially Deacylated Poly(2-alkyl-2-oxazoline) Antipathogen Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antimicrobial/antiviral/antifungal formulations, solutions, films, and coatings that are relatively non-toxic and effective.
Innovation Solution
The development of antimicrobial/antiviral/antifungal formulations, solutions, films, and coatings using tuned cationic polymers, which are partially deacylated poly(2-alkyl-2-oxazoline) copolymers with a total cationic charge in the range of 0.2 to 10 C/cm3, offset by counteranions, that inactivate at least ninety percent of pathogens within ninety minutes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antimicrobial formulations are used, then antimicrobial activity is achieved, but toxicity to humans, animals, and the environment increases
Solution Approach 1:
The patent modifies the chemical structure of poly(2-alkyl-2-oxazoline) by changing the alkyl chain length parameter (from C1-C6 to C7-C18) and controlling the degree of deacylation (5-50% deacylation) to achieve optimal balance between antimicrobial efficacy and reduced toxicity. This systematic parameter optimization allows the polymer to maintain pathogen inactivation capability while minimizing harmful effects on humans, animals, and the environment.
Solution Approach 2:
The patent creates a composite system by combining partially deacylated poly(2-alkyl-2-oxazoline) with complementary polymers or additives to enhance antimicrobial activity while maintaining safety profile. The composite formulation leverages the inherent properties of the oxazoline polymer backbone while using auxiliary components to boost efficacy against specific pathogens without increasing toxicity.
2Object-affected harmful factors
If poly(2-alkyl-2-oxazoline) is fully deacylated to reduce toxicity, then safety improves, but antimicrobial activity decreases
Solution Approach 1:
The patent applies partial deacylation (5-50% deacylation) rather than complete deacylation, strategically retaining some acyl groups to maintain antimicrobial activity while removing sufficient portions to reduce toxicity. This partial action approach optimizes the balance between the two opposing requirements, achieving both safety and efficacy simultaneously.
Solution Approach 2:
The patent optimizes the degree of deacylation parameter to fall within the specific range of 5-50%, which has been determined to provide the optimal balance between antimicrobial activity and toxicity reduction. This precise parameter control ensures that enough acyl groups remain to maintain pathogen inactivation capability while enough are removed to achieve the desired safety profile.
3Object-affected harmful factors
If shorter alkyl chains are used in poly(2-alkyl-2-oxazoline), then toxicity decreases, but membrane penetration ability worsens
Solution Approach 1:
The patent optimizes the alkyl chain length parameter within the specific range of C7-C18, which provides the optimal balance between membrane penetration ability and reduced toxicity. This parameter optimization ensures that the polymer can effectively penetrate pathogen membranes while maintaining acceptable safety profile, resolving the contradiction between these two properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tuned polymer-based formulations demonstrate high efficacy in inactivating pathogens, providing long-lasting antimicrobial action, and passing rigorous durability tests such as EPA 01-1A and PAS2424, ensuring safety for humans, animals, and the environment.
Implementation Method 1
The polymer is cationic and has a total cationic charge in the range of 0.2 to 10 C/cm3
Data Source
AI summary
A method for inactivating pathogens is described, comprising the steps of: partially deacylating a poly(2-alkyl-2-oxazoline) to yield a copolymer, an alkyl in the poly(2-alkyl-2-oxazoline) comprising a hydrocarbon chain, the copolymer comprising: first monomers, the first monomers comprising a —NH2+CH2CH2— group; and second monomers, the second monomers comprising an acyl group, —C(═O)—R′, attached to a nitrogen in a polymer backbone group comprising —NCH2CH2—, wherein R′ comprises the hydrocarbon chain, the first monomers and the second monomers arranged in any order in the copolymer; preparing a formulation, the formulation comprising the copolymer and a total cationic charge in a range of 0.2 to 10 C/cm3, the total cationic charge at least 95% offset by counteranions in the formulation; contacting the pathogens with the formulation; and inactivating at least ninety percent of the pathogens within ninety minutes of the step of contacting.